Publications by authors named "F Lutz"
Background: Claudin-3 (CLDN3) participates in the formation of the tight-junctions (TJs) that regulate intercellular permeability. Altered CLDN3 expression has been linked to tumor progression in multiple tumor types. Despite its widespread expression in normal epithelial cells, CLDN3 is considered an attractive drug target candidate, since it may be more accessible in cancer cells than in normal cells due to their less orchestrated cell growth.
View Article and Find Full Text PDFPAX6 immunohistochemistry (IHC) was proposed as a tool to identify a pancreatic origin of neuroendocrine neoplasms (NENs). To evaluate the diagnostic utility of PAX6 IHC, a tissue microarray containing 19,214 samples from 150 tumor types was analyzed. Data on progesterone receptor (PR) and glutamate decarboxylase 2 (GAD2) expression were available from previous studies.
View Article and Find Full Text PDFArticle Synopsis
- Anterior gradient 2 (AGR2) is a key protein involved in various biological processes like embryonic development, tissue regeneration, and wound healing, with potential implications in cancer research.
- A comprehensive analysis of nearly 15,000 tumors and normal tissue samples revealed that AGR2 expression is present in a majority of tumor categories, particularly in tumors of the female genital tract and various adenocarcinomas.
- High levels of AGR2 are associated with poor clinical outcomes in several cancer types, suggesting its role as a potential biomarker for tumor aggressiveness and progression.
Trefoil factor 1 (TFF1) plays a role in the mucus barrier. To evaluate the prevalence of TFF1 expression in cancer, a tissue microarray containing 18,878 samples from 149 tumor types and 608 samples of 76 normal tissue types was analyzed through immunohistochemistry (IHC). TFF1 staining was detectable in 65 of 149 tumor categories.
View Article and Find Full Text PDFArticle Synopsis
- Loss of S-methyl-5'-thioadenosine phosphorylase (MTAP) is commonly seen in various cancers, making these cells more vulnerable to anti-cancer drugs.
- A study analyzed over 17,000 tumor samples and found complete MTAP loss in 83 out of 149 tumor types, particularly noting high rates in neuroendocrine tumors and Hodgkin lymphoma.
- MTAP deficiency is associated with negative tumor characteristics, such as a lack of immune cell infiltration and lower CD8+ lymphocyte density, indicating its potential as a significant diagnostic marker in cancer.